# **ODN 2006 VacciGrade™**

CpG ODN, type B (human); TLR9-based adjuvant

Catalog code: vac-2006-1

https://www.invivogen.com/odn2006-vaccigrade

For research use only. Not for use in humans.

Version 20A30-MM

# PRODUCT INFORMATION

#### Contents

- 1 mg (129.8 nmol) lyophilized ODN 2006 VacciGrade<sup>™</sup>
- 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

### ODN 2006 sequence

5'-tcgtcgttttgtcgttttgtcgtt-3' (24 mer) <u>Note:</u> Bases are phosphorothioate (nuclease resistant).

#### Storage and stability

- ODN 2006 VacciGrade<sup>™</sup> is shipped at room temperature and should be stored at -20°C for 1 year when properly stored.
- Upon resuspension, prepare aliquots of ODN 2006 VacciGrade<sup>™</sup> and store at -20°C. Product is stable for 6 months at -20°C when properly stored. Avoid repeated freeze-thaw cycles.

### Quality control

ODN 2006 VacciGrade<sup>™</sup> is a preclinical grade preparation of the CpG ODN 2006. It is prepared under strict aseptic conditions and is tested for the presence of endotoxins. ODN 2006 VacciGrade<sup>™</sup> is guaranteed sterile and its endotoxin level is <2 EU/mg (determined using an in-house proprietary monocyte activation assay).

#### **MFTHODS**

Working Concentrations: 20-50 µg/mouse

### Preparation of sterile stock solution (2 mg/ml)

- Add 500 µl of the endotoxin-free physiological water provided to 1 mg ODN 2006 VacciGrade<sup>™</sup> to obtain a solution at 2 mg/ml.
- Mix the solution by pipetting up and down.

## **DESCRIPTION**

Synthetic oligodeoxynucleotides containing unmethylated CpG motifs (CpG ODNs), such as ODN 2006 (also known as ODN 7909 or PF-3512676), have been extensively studied as adjuvants<sup>1</sup>. These CpG motifs are present at a 20-fold greater frequency in bacterial DNA compared to mammalian DNA<sup>2</sup>. CpG ODNs are recognized by TLR9, which is expressed exclusively on human B cells and plasmacytoid dendritic cells, thereby inducing Th1-dominated immune responses<sup>3</sup>. Pre-clinical studies conducted in rodents and non-human primates and human clinical trials have demonstrated that CpG ODNs can significantly improve vaccine-specific antibody responses<sup>1</sup>.

Three types of stimulatory CpG ODNs have been identified, types A, B and C, which differ in their immune-stimulatory activities<sup>4-5</sup>. Moreover, CpG ODNs activate TLR9 in a species-specific manner<sup>6</sup>. ODN 1826 VacciGrade<sup>11</sup> is a type B CpG ODN specific for mouse TLR9. Type B CpG ODNs contain a full phosphorothioate backbone with one or more CpG dinucleotides and can strongly activate B cells<sup>4</sup>.

ODN 2006 has been tested as an adjuvant in numerous animal models<sup>7-9</sup>. Research has demonstrated that ODN 2006 is an effective adjuvant for stimulating both antibody<sup>8,9</sup> and interferon-mediated cellular immune responses<sup>9</sup>.

1. Steinhagen F. et al., 2010. TLR-based immune adjuvants. Vaccine 29(17):3341-55.
2. Hemmi H. et al., 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-5. 3. Coffman RL. et al., 2010. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4):492-503. 4. Krug A. et al., 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol, 31(7): 2154-63. 5. Marshall JD. et al., 2005. Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24(2):63-72. 6. Bauer, S. et al., 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. PNAS 98(16):9237-42. 7. Hartmann G. et al., 2000. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164(3):1617-24. 8. Conforti VA. et al., 2007. The effectiveness of a CpG motif-based adjuvant (CpG ODN 2006) for LHRH immunization. Vaccine 25: 6537-43. 9. Zhang Y. et al., 2003. CpG ODN 2006 and IL-12 are comparable for priming Th1 lymphocyte and IgG responses in cattle immunized with a rickettsial outer membrane protein in alum. Vaccine 21:3307-18.

### RFI ATFD PRODUCTS

Product	Description	Cat. Code
2'3'-cGAMP VacciGrade <sup>™</sup>	STING agonist	vac-nacga23
Alhydrogel® adjuvant 2%	Al(OH) <sub>3</sub> gel	vac-alu-250
CFA	Complete Freund's Adjuvant	vac-cfa-10
ODN 1826 VacciGrade <sup>™</sup>	Murine TLR9 agonist	vac-1826-1
Poly(I:C) VacciGrade <sup>™</sup>	TLR3 agonist	vac-pic

For a complete list of adjuvants provided by InvivoGen, please visit <a href="https://www.invivogen.com/vaccine-adjuvants">https://www.invivogen.com/vaccine-adjuvants</a>.



InvivoGen USA (Toll-Free): 888-457-5873 InvivoGen USA (International): +1 (858) 457-5873 InvivoGen Europe: +33 (0) 5-62-71-69-39 InvivoGen Hong Kong: +852 3-622-34-80

E-mail: info@invivogen.com

